What values do the public want their health care systems to use in evaluating technologies?
作者信息
Buxton Martin J, Chambers James D
出版信息
Eur J Health Econ. 2011 Aug;12(4):285-8. doi: 10.1007/s10198-011-0320-4.
Abstract
摘要
相似文献
1
What values do the public want their health care systems to use in evaluating technologies?公众希望他们的医疗保健系统在评估技术时采用哪些价值观？
Eur J Health Econ. 2011 Aug;12(4):285-8. doi: 10.1007/s10198-011-0320-4.
2
Diffusion of high technology medical care and cost control--a public policy dilemma.高科技医疗护理的普及与成本控制——一个公共政策困境。
Technol Soc. 1981;3(3):305-22. doi: 10.1016/0160-791x(81)90002-6.
3
[Health technology assessment: II. Cost effectiveness analysis].[卫生技术评估：II. 成本效益分析]
Arq Gastroenterol. 2010 Oct-Dec;47(4):329-33. doi: 10.1590/s0004-28032010000400002.
4
Should transplantation be a part of a health care system?移植应该成为医疗保健系统的一部分吗？
Can Fam Physician. 1990 Jun;36:1129-32.
5
Evaluating new health information technologies: expanding the frontiers of health care delivery and health promotion.评估新型健康信息技术：拓展医疗服务与健康促进的前沿领域。
Stud Health Technol Inform. 2002;80:205-12.
6
Values and evidence colliding: health technology assessment in child health.价值观与证据的碰撞：儿童健康领域的卫生技术评估
Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):417-9. doi: 10.1586/14737167.2013.815420.
7
The future impact of science and technology on medicine: basic research.科学技术对医学的未来影响：基础研究
Vital Speeches Day. 1973 Nov 15;40(2):75-80.
8
Controlling health care costs by controlling technology: a private contractual approach.通过控制技术来控制医疗保健成本：一种私人契约方法。
Yale Law J. 1990 Mar;99(5):1109-26.
9
Cost/benefit analysis-another dimension.成本效益分析——另一个维度。
Med Instrum. 1982 Jan-Feb;16(1):76-7.
10
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.估算澳大利亚卫生系统的参考增量成本-效果比。
Pharmacoeconomics. 2018 Feb;36(2):239-252. doi: 10.1007/s40273-017-0585-2.
引用本文的文献
1
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?采用传统成本效益分析评估孤儿药的价值：是否合适？
Orphanet J Rare Dis. 2022 Apr 5;17(1):157. doi: 10.1186/s13023-022-02283-z.
2
The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.泛加拿大肿瘤药物评审成员与加拿大公众的优先排序偏好：一项陈述偏好比较
Curr Oncol. 2016 Oct;23(5):322-328. doi: 10.3747/co.23.3033. Epub 2016 Oct 25.
3
What, who and when? Incorporating a discrete choice experiment into an economic evaluation.什么、谁和何时？将离散选择实验纳入经济评价。
Health Econ Rev. 2016 Dec;6(1):31. doi: 10.1186/s13561-016-0108-4. Epub 2016 Jul 29.
4
Health economics and health technology assessment in Central and Eastern Europe: a dose of reality.中东欧地区的卫生经济学与卫生技术评估：一剂现实良药。
Eur J Health Econ. 2012 Oct;13(5):525-31. doi: 10.1007/s10198-012-0411-x.
本文引用的文献
1
Listening to Provenge--what a costly cancer treatment says about future Medicare policy.聆听“普罗文奇”——一种昂贵的癌症治疗方法对未来医疗保险政策的启示。
N Engl J Med. 2011 May 5;364(18):1687-9. doi: 10.1056/NEJMp1103057. Epub 2011 Apr 6.
2
Deriving distributional weights for QALYs through discrete choice experiments.通过离散选择实验推导出 QALYs 的分布权重。
J Health Econ. 2011 Mar;30(2):466-78. doi: 10.1016/j.jhealeco.2011.01.003. Epub 2011 Jan 17.
3
A French approach to cost-effectiveness analysis?一种法国式的成本效益分析方法？
Eur J Health Econ. 2010 Dec;11(6):521-3. doi: 10.1007/s10198-010-0284-9.
4
On the welfare theoretic foundation of CEA: comment.关于成本效果分析的福利理论基础：评论。
Eur J Health Econ. 2010 Dec;11(6):595-6; discussion 597-8. doi: 10.1007/s10198-010-0282-y. Epub 2010 Oct 15.
5
Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.利用比较效果研究为英国 HHS 的政策和实践提供信息：过去、现在和未来。
Pharmacoeconomics. 2010;28(10):799-811. doi: 10.2165/11535260-000000000-00000.
6
Does Medicare have an implicit cost-effectiveness threshold?医疗保险是否存在隐含的成本效益阈值？
Med Decis Making. 2010 Jul-Aug;30(4):E14-27. doi: 10.1177/0272989X10371134. Epub 2010 Jun 15.
7
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.乳腺癌筛查：美国预防服务工作组推荐声明。
Ann Intern Med. 2009 Nov 17;151(10):716-26, W-236. doi: 10.7326/0003-4819-151-10-200911170-00008.
8
On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.在不影响生存的情况下，基于成本效益分析的福利理论基础。
Eur J Health Econ. 2010 Feb;11(1):5-13. doi: 10.1007/s10198-009-0145-6. Epub 2009 Mar 3.
9
Exploring the social value of health-care interventions: a stated preference discrete choice experiment.探索医疗保健干预措施的社会价值：一项陈述偏好离散选择实验。
Health Econ. 2009 Aug;18(8):951-76. doi: 10.1002/hec.1414.
10
What should be given a priority - costly medications for relatively few people or inexpensive ones for many? The Health Parliament public consultation initiative in Israel.应该优先考虑什么——为相对少数人提供昂贵的药物，还是为许多人提供便宜的药物？以色列的健康议会公众咨询倡议。
Health Expect. 2008 Jun;11(2):177-88. doi: 10.1111/j.1369-7625.2007.00485.x. Epub 2008 Apr 21.
Zotero 插件